Edition:
India

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

75.25USD
1:31am IST
Change (% chg)

$0.92 (+1.24%)
Prev Close
$74.33
Open
$74.03
Day's High
$75.54
Day's Low
$74.03
Volume
713,991
Avg. Vol
879,511
52-wk High
$82.25
52-wk Low
$61.06

Latest Key Developments (Source: Significant Developments)

Baxter International Says CEO José Almeida's FY 2018 Compensation Was $15.6 Mln
Wednesday, 27 Mar 2019 

March 26 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL INC SAYS CEO JOSÉ ALMEIDA'S FY 2018 TOTAL COMPENSATION WAS $15.6 MILLION VERSUS $14.9 MILLION IN FY 2017 - SEC FILING.BAXTER INTERNATIONAL INC SAYS RATIO OF CEO ANNUAL TOTAL COMPENSATION FOR 2018 TO ANNUAL TOTAL COMPENSATION OF EMPLOYEE IS 346 TO 1.  Full Article

Baxter And Biomérieux Collaborate On Identification And Treatment Of Acute Kidney Injury
Tuesday, 19 Mar 2019 

March 19 (Reuters) - BAXTER INTERNATIONAL INC ::BAXTER AND BIOMÉRIEUX ANNOUNCE COLLABORATION TO IMPROVE IDENTIFICATION AND TREATMENT OF ACUTE KIDNEY INJURY.  Full Article

Baxter International Q4 GAAP Earnings Per Share $0.66 From Continuing Operations
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Baxter International Inc ::BAXTER REPORTS 2018 FOURTH-QUARTER AND FULL-YEAR RESULTS.Q4 GAAP EARNINGS PER SHARE $0.66 FROM CONTINUING OPERATIONS.Q4 REVENUE $2.8 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.8 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.73 -- REFINITIV IBES DATA.SEES Q1 2019 ADJUSTED EARNINGS PER SHARE $0.66 TO $0.68 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.22 TO $3.30 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q4 ADJUSTED EARNINGS PER SHARE $0.78 FROM CONTINUING OPERATIONS.FOR FULL-YEAR 2019 EXPECTS SALES GROWTH OF 0 TO 1 PERCENT ON A REPORTED BASIS.FOR FIRST-QUARTER 2019 COMPANY EXPECTS SALES TO DECLINE ABOUT 3 PERCENT ON A REPORTED BASIS.  Full Article

Baxter Starts U.S. Clinical Trial For On-Demand Peritoneal Dialysis Solution System
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Baxter International Inc ::BAXTER STARTS U.S. CLINICAL TRIAL FOR ON-DEMAND PERITONEAL DIALYSIS SOLUTION SYSTEM.BAXTER INTERNATIONAL INC - FOOD AND DRUG ADMINISTRATION (FDA) HAS INDICATED THAT COMPANY MAY PROCEED WITH PROSPECTIVE, MULTI-CENTER CLINICAL TRIAL..BAXTER - AFTER CONCLUSION OF TRIAL, STUDY REPORTING PROCESS, CO EXPECTS TO SUBMIT NDA FOR CONCENTRATES AND 510(K) FOR DEVICE TO FDA.  Full Article

UK's CMA Not To Refer Baxter-Hospira Deal To Phase II Probe
Friday, 4 Jan 2019 

Jan 4 (Reuters) - UK's CMA::UK'S CMA- CMA HAS DECIDED NOT TO REFER ACQUISITION BY BAXTER INTERNATIONAL. OF HOSPIRA UKS COMPOUNDING BUSINESS AND RELATED ASSETS. TO PHASE II.  Full Article

Third Point LLC Says On Dec 3, Sold Aggregate Of 8 Mln Shares Of Baxter International's Common Stock In Block Trade At $68.62 Per Share - SEC Filing
Wednesday, 5 Dec 2018 

Dec 4 (Reuters) - THIRD POINT LLC::THIRD POINT LLC SAYS ON DEC 3, SOLD AGGREGATE OF 8.0 MILLION SHARES OF BAXTER INTERNATIONAL'S COMMON STOCK IN BLOCK TRADE AT $68.62 PER SHARE - SEC FILING.  Full Article

Baxter declares quarterly dividend and announces expanded share repurchase authorization
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Baxter International Inc ::BAXTER DECLARES QUARTERLY DIVIDEND AND ANNOUNCES EXPANDED SHARE REPURCHASE AUTHORIZATION.BAXTER INTERNATIONAL INC - APPROVED A $2.0 BILLION INCREASE IN AUTHORIZATION FOR COMPANY'S EXISTING SHARE REPURCHASE PLAN.BAXTER INTERNATIONAL INC - SHARE REPURCHASE PLAN HAS APPROXIMATELY $3.4 BILLION OF REPURCHASE AUTHORITY AVAILABLE AS OF DATE HEREOF.  Full Article

Baxter Expects Sales To Grow ~5 Pct On Compounded Annual Basis At Constant Currency Rates From 2018 To 2023
Monday, 21 May 2018 

May 21 (Reuters) - Baxter International Inc ::BAXTER HIGHLIGHTS BUSINESS STRATEGIES AND INNOVATION AT 2018 INVESTOR CONFERENCE.BAXTER INTERNATIONAL INC - BAXTER EXPECTS TO GROW SALES 4 TO 5 PERCENT ON A COMPOUNDED ANNUAL BASIS AT CONSTANT CURRENCY RATES FROM 2018 THROUGH 2020.BAXTER INTERNATIONAL INC - NOW EXPECTS A 2020 ADJUSTED OPERATING MARGIN OF 20 TO 21 PERCENT AND ADJUSTED DILUTED EARNINGS OF $3.60 TO $3.75 PER SHARE.BAXTER INTERNATIONAL INC - NOW EXPECTS FREE CASH FLOW (OPERATING CASH FLOW LESS CAPITAL EXPENDITURES) OF APPROXIMATELY $2.1 BILLION IN 2020.BAXTER INTERNATIONAL - EXPECTS SALES TO GROW APPROXIMATELY 5 PERCENT ON A COMPOUNDED ANNUAL BASIS AT CONSTANT CURRENCY RATES FROM 2018 TO 2023.BAXTER INTERNATIONAL - IN 2023, ANTICIPATES AN ADJUSTED OPERATING MARGIN OF 23 TO 24 PERCENT AND ADJUSTED DILUTED EARNINGS OF $4.90 TO $5.05 PER SHARE.BAXTER INTERNATIONAL INC - ALSO EXPECTS TO GENERATE FREE CASH FLOW OF APPROXIMATELY $2.65 BILLION IN 2023.  Full Article

Baxter Reports Q4 Adjusted EPS Of $0.64​
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Baxter International Inc ::BAXTER REPORTS 2017 FOURTH-QUARTER AND FULL-YEAR RESULTS.Q4 GAAP LOSS PER SHARE $0.11 FROM CONTINUING OPERATIONS.Q4 REVENUE $2.8 BILLION VERSUS I/B/E/S VIEW $2.77 BILLION.Q4 EARNINGS PER SHARE VIEW $0.59 -- THOMSON REUTERS I/B/E/S.SEES Q1 EARNINGS PER SHARE $0.60 TO $0.62 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2018 EARNINGS PER SHARE $2.72 TO $2.80 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q4 WORLDWIDE SALES TOTALED ABOUT $2.8 BILLION, UP 5 PERCENT ON REPORTED BASIS, 3 PERCENT ON CONSTANT CURRENCY BASIS​.BAXTER - Q4 REVENUE NEGATIVELY IMPACTED BY ABOUT $70 MILLION FROM TEMPORARY MANUFACTURING DISRUPTIONS IN PUERTO RICO DUE TO IMPACT OF HURRICANE MARIA.QTRLY ‍ADJUSTED EPS OF $0.64​.QTRLY ‍SALES IN U.S. WERE $1.1 BILLION, INCREASING 1 PERCENT​.BAXTER INTERNATIONAL - QTRLY ‍INTERNATIONAL SALES TOTALED MORE THAN $1.6 BILLION, REPRESENTING 8 PERCENT INCREASE ON REPORTED BASIS​.BAXTER - Q1 SALES WILL BE NEGATIVELY IMPACTED BY ABOUT $25 MILLION DUE TO DISRUTIONS IN PUERTO RICO.FOR FULL-YEAR 2018, BAXTER EXPECTS SALES GROWTH OF 6 TO 7 PERCENT ON A REPORTED BASIS.FOR Q1, COMPANY EXPECTS SALES GROWTH OF APPROXIMATELY 5 TO 6 PERCENT ON A REPORTED BASIS.BAXTER - ALL PUERTO RICO FACILITIES ARE BACK ON ELECTRICAL GRID & HAVE BEEN RAMPING UP PRODUCTION TO PRE-HURRICANE LEVELS.FOR Q1, OPERATIONAL SALES ARE EXPECTED TO BE FLAT TO UP 1 PERCENT AS COMPARED TO PRIOR-YEAR PERIOD.SEES ‍Q1 2018 GAAP EARNINGS PER SHARE $0.45 - $0.49​.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

U.S. closes IV solution shortage antitrust probe, Baxter says

Baxter International Inc said the U.S. Justice Department has closed an antitrust probe examining possible communication among producers of intravenous saline solutions during supply shortages that created higher prices.